References
- FDA Drug Safety Communication: FDA warns that prescribing of Nizoral (ketoconazole) oral tablets for unapproved uses including skin and nail infections continues; linked to patient death Food and Drug Administration. [Accessed 2020 Aug 21]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-prescribing-nizoral-ketoconazole-oral-tablets-unapproved.
- Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia. 2017;182(1–2):127–141.
- Gupta AK, Lyons DC. The rise and fall of oral ketoconazole. J Cutan Med Surg. 2015;19(4):352–357.
- FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems Food and Drug Administration. 2016 [Accessed 2020 Aug 25]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially.
- National Ambulatory Medical Care Survey CDC. 2016. https://www.cdc.gov/nchs/ahcd/datasets_documentation_related.htm.
- 2016 Micro-Data File Documentation. [Accessed 2020 Apr 28]. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/doc2016.pdf.
- Leon AC. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments. J Clin Psychiat. 2004;65(11):1511–1514.